# Pharmacological Reduction of Right Ventricular Enlargement

> **NCT04345796** · PHASE3 · COMPLETED · sponsor: **Asan Medical Center** · enrollment: 56 (actual)

## Conditions studied

- Tricuspid Regurgitation
- Right Ventricular Dilatation

## Interventions

- **DRUG:** Carvedilol+Empagliflozin
- **DRUG:** Carvedilol
- **DRUG:** Empagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04345796
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-15
- **Primary completion:** 2024-06-03
- **Final completion:** 2024-06-03
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2025-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04345796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04345796, "Pharmacological Reduction of Right Ventricular Enlargement". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04345796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*